Login to Your Account



Clinic Roundup


Tuesday, April 17, 2012
• Morphotek Inc., of Exton, Pa., a subsidiary of Eisai Inc., began a Phase II trial of MORAb-004 for colorectal cancer. The randomized, double-blind, placebo-controlled trial will evaluate safety and efficacy of single-agent MORAb-004 with supportive care for progression-free survival in patients with chemo-refractory metastatic colorectal cancer. Secondary endpoints include overall survival and identification of efficacy biomarkers.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription